Tagworks will present how its Click-to-Release platform affords in vivo control over drug activity to address the limited therapeutic window and application scope of several targeted cancer therapies, applied to ADCs (i.e. TGW101, Tagworks’ lead clinical program) as well as targeted radiotherapies. The Antibody Engineering & Therapeutics Europe Conference will …